Early in vivo signaling profiles in MUC1-specific CD4+ T cells responding to two different MUC1-targeting vaccines in two different microenvironments

Dawn K. Reichenbach, Olivera J. Finn

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Vaccines are beginning to be explored for as measures to prevent cancer. Since determining the efficacy of vaccines by evaluating disease outcome requires a long time, there is an urgent need for early predictive biomarkers. To this end, immunological endpoints that can be assessed weeks or months post-vaccination are currently being evaluated. However, when multiple vaccines are available, waiting for the development of humoral and cellular immunity could still cause delays, whereas early assessments would allow for a timely shift to more effective prevention modalities. Applying the phospho-flow technique to primary T cells, we examined the phosphorylation status of various proteins that shape the activation, proliferation, and differentiation of mucin 1 (MUC1)-specific CD4+ T cells within the first 24 hours postimmunization. It is known that a vaccine composed of a MUC1-derived peptide loaded on dendritic cells is more effective in eliciting T-cell responses than a vaccine including the same peptide plus an adjuvant. Both these vaccines stimulate T cells more effectively in wild-type (WT) than in MUC1-transgenic mice. We examined if the signaling events downstream of the TCR or linked to various proliferative and survival pathways, monitored in two different hosts as early as 3, 6, 12 and 24 hours post-immunization, could predict the differential potential of these two MUC1-targeting vaccines. The signaling signatures that we obtained primarily reflect differences between the vaccines rather than between the hosts. We demonstrate the feasibility of using a phospho-flow-based approach to evaluate the potential of a given vaccine to elicit a desired immune response.

Original languageEnglish (US)
Article numbere23429
Issue number3
StatePublished - Mar 2013
Externally publishedYes

Bibliographical note

Funding Information:
We would like to thank Dr. Stephen H. Thorne, Adam Farkas and Douglas Marvel for helpful discussions and Jia Xue for technical help. We are grateful to Dr. Andres Salazar and Oncovir Inc. for the gift of Hiltonol. This work was supported by the National Institutes of Health grant R01 CA056103 and RO1 CA168392 (OJF). DKR was supported by NIAID T32 AI089443.


  • Cancer
  • Phospho-flow
  • Self antigen
  • Tolerance
  • Transgenic mice
  • Tumor antigen
  • Vaccine


Dive into the research topics of 'Early in vivo signaling profiles in MUC1-specific CD4+ T cells responding to two different MUC1-targeting vaccines in two different microenvironments'. Together they form a unique fingerprint.

Cite this